The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia
Posted by Adam Awdish on
Pooled Human AB Serum Off The Clot Heat Inactivated from Innovative Research was used in the following study:
The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia
Svetlana Vakkilainen, Iivari Kleino, Jarno Honkanen, Harri Salo, Leena Kainulainen, Michaela Gräsbeck, Eliisa Kekäläinen, Outi Mäkitie, and Paula Klemetti
Frontiers in Immunology
August 11, 2020
Cartilage-hair hypoplasia (CHH) is a rare skeletal dysplasia with combined immunodeficiency that is caused by genetic mutations. The degree of immunodeficiency experienced by patients with CHH can vary greatly, ranging from asymptomatic lymphopenia to severe deficiencies requiring stem cell transplants. Because of this, patients with CHH can potentially develop fatal complications after administration of live viral vaccines, and therefore live vaccines are generally not recommended for patients with combined immunodeficiency.
Researchers in this study immunized four children and one adult, all with clinically silent immunodeficiencies. The patients were subcutaneously given one or two doses of Varilrix®, a live-attenuated VZV Oka strain vaccine, and blood samples were drawn pre-immunization and 4-6 weeks post-immunization for evaluation of humoral and cellular responses.
None of the immunized children developed adverse events. Patient 5 reported a minor respiratory infection and rash shortly after immunization. The patient declined antiviral and anti-inflammatory therapy and reported no complaints on the follow-up seven weeks post-immunization. All patients demonstrated the development of cellular response post-immunization, four of which were after the first vaccine dose.
Related products available from Innovative Research also include:
Pooled Human Plasma (Blood Derived)